Search Results - "BAIN, V."

Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy by Sherman, M, Yoshida, E M, Deschenes, M, Krajden, M, Bain, V G, Peltekian, K, Anderson, F, Kaita, K, Simonyi, S, Balshaw, R, Lee, S S

“…Background: The management of patients with chronic hepatitis C who have relapsed or failed to respond to interferon based therapies is an important issue…”
Get full text

Contributions of pocket depth and electrostatic interactions to affinity and selectivity of receptors for methylated lysine in water by Beaver, Joshua E, Peacor, Brendan C, Bain, Julianne V, James, Lindsey I, Waters, Marcey L

“…Dynamic combinatorial chemistry was used to generate a set of receptors for peptides containing methylated lysine (KMen, n = 0-3) and study the contribution of…”
Get more information

Rotterdam score predicts early mortality in Budd‐Chiari syndrome, and surgical shunting prolongs transplant‐free survival by MONTANO‐LOZA, A. J., TANDON, P., KNETEMAN, N., BAILEY, R., BAIN, V. G.

“…Summary Background  Budd–Chiari syndrome carries significant mortality, but factors predicting this outcome are uncertain. Aim  To determine factors associated…”
Get full text

Treating chronic hepatitis C with pegylated interferon alfa‐2a (40 KD) and ribavirin in clinical practice by LEE, S. S., BAIN, V. G., PELTEKIAN, K., KRAJDEN, M., YOSHIDA, E. M., DESCHENES, M., HEATHCOTE, J., BAILEY, R. J., SIMONYI, S., SHERMAN, M.

“…Summary Background Pegylated interferon alfa‐2a (40 KD) plus ribavirin therapy induces sustained virological response rates up to 63% in randomized‐controlled…”
Get full text

Moving inwards, moving outwards, moving upwards: the role of spirituality during the early stages of breast cancer by SWINTON, J., BAIN, V., INGRAM, S., HEYS, S.D.

“…SWINTON J., BAIN V., INGRAM S. & HEYS S.D. (2011) European Journal of Cancer Care20, 640–652 Moving inwards, moving outwards, moving upwards: the role of…”
Get full text

Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa‐2a plus ribavirin by BAIN, V. G., LEE, S. S., PELTEKIAN, K., YOSHIDA, E. M., DESCHÊNES, M., SHERMAN, M., BAILEY, R., WITT‐SULLIVAN, H., BALSHAW, R., KRAJDEN, M.

“…Summary Background  The impact of reduced drug exposure on outcomes in patients with chronic hepatitis C has not been determined in routine clinical practice…”
Get full text

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo by Tipples, GA, Ma, MM, Fischer, KP, Bain, VG, Kneteman, NM, Tyrrell, DL

“…The (-) enantiomer of 3'-thiacytidine (lamivudine) has been found to be a potent inhibitor of hepatitis B virus (HBV) and human immunodeficiency virus (HIV)…”
Get full text

Reverse transcriptase activity in patients with primary biliary cirrhosis and other autoimmune liver disorders by MCDERMID, J., CHEN, M., LI, Y., WASILENKO, S., BINTNER, J., MCDOUGALL, C., PANG, X., BAIN, V. G., MASON, A. L.

“…Summary Background  Patients with biliary disease make retroviral antibodies and the Human Betaretrovirus has been characterized in patients with primary…”
Get full text

Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials by TANDON, P., BAIN, V. G., TSUYUKI, R. T., KLARENBACH, S.

“…Summary Background Although reversal of pretransplant renal dysfunction in hepatorenal syndrome reduces post‐transplant complications, the overall impact on…”
Get full text

111 SARCOPENIA PREDICTS EARLY MORTALITY IN PATIENTS WITH CIRRHOSIS by Montano-Loza, A.J, Meza-Junco, J, Prado, C, Lieffers, J, Baracos, V, Bain, V, Sawyer, M

Get full text

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3 by Powis, J., Peltekian, K. M., Lee, S. S., Sherman, M., Bain, V. G., Cooper, C., Krajden, M., Deschenes, M., Balshaw, R. F., Heathcote, E. Jenny, Yoshida, E. M.

“…Chronic hepatitis C virus (HCV) infections with genotype 2 or 3 are associated with favourable sustained virologic response (SVR) rates. However, genotype 3…”
Get full text

Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation by BAIN, V. G, KNETEMAN, N. M, MA, M. M, GUTFREUND, K, SHAPIRO, J. A, FISCHER, K, TIPPLES, G, LEE, H, JEWELL, L. D, TYRRELL, D. L

“…Liver transplantation for endstage hepatitis B virus (HBV) infection has been associated with survival inferior to that of liver transplantation in other…”
Get full text

1042 EFFICACY AND SAFETY RESULTS OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN INTERFERON-ALFA TREATMENT NAIVE PATIENTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C by Nelson, D, Benhamou, Y, Chuang, W.L, Lawitz, E, Flisiak, R, Rodriguez-Torres, M, Bain, V, Patel, K, Cronin, P.W, Pulkstenis, E, Subramanian, G.M, McHutchison, J.G

Get full text

819 HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ALBINTERFERON ALFA-2B PLUS RIBAVIRIN IN IFN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C by Pianko, S, Yoshida, E, Zeuzem, S, Benhamou, Y, Bain, V, Pulkstenis, E, McHutchison, J.G, Subramanian, G.M

Get full text

A multicentre study of the usefulness of liver biopsy in hepatitis C by Bain, V. G., Bonacini, M., Govindarajan, S., Ma, M., Sherman, M., Gibas, A., Cotler, S. J., Deschenes, M., Kaita, K., Jhangri, G. S.

“…The role of liver biopsy in the assessment of chronic hepatitis C is generally accepted yet there is no prospective data available to quantify its…”
Get full text

Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance by Gutfreund, Klaus S, Williams, Mark, George, Rajan, Bain, Vincent G, Ma, Mang M, Yoshida, Eric M, Villeneuve, Jean-Pierre, Fischer, Karl P, Tyrrell, David L.J

“…Background/Aims: Hepatitis B mutant strains of virus emerging during treatment with the nucleoside analog lamivudine are being increasingly recognized. In the…”
Get full text

[615] MANAGEMENT OF CHRONIC HEPATITIS C IN A DIVERSE POPULATION WITH PEGINTERFERON tt-2a AND RIBAVIRIN: FINAL RESULTS OF THE CANADIAN PEGASYS EXPANDED ACCESS PROGRAM (EAP) by Deschenes, M, Yoshida, E, Peltekian, K, Cooper, C, Bain, V, Krajden, M, Sherman, M, Lee, S.S, Balshaw, R, Marotta, P

Get full text

Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics by Everson, Gregory T., Jensen, Donald M., Craig, John R., van Leeuwen, Dirk J., Bain, Vincent G., Ehrinpreis, Murray N., Albert, Donald, Joh, Tenshang, Witt, Karsten

“…Chronic hepatitis C patients (472 patients) were treated with consensus interferon (CIFN) or interferon (IFN) alfa‐2b for 6 months in a large multicenter…”
Get full text

12 HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR AND GS-9256 WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS by Nelson, D.R, Lawitz, E, Bain, V, Gitlin, N, Hawkins, T, Marotta, P, Workowski, K, Flamm, S, Pang, P.S, McHutchison, J.G, McNally, J, Urbanek, P, Yoshida, E.M

Get full text

Rapid resolution of chylous ascites after liver transplantation using somatostatin analog and total parenteral nutrition by SHAPIRO, A. M. J, BAIN, V. G, SIGALET, D. L, KNETEMAN, N. M

“…Chylous ascites is the accumulation of chylomicronrich lymphatic fluid within the peritoneal cavity. It is a rare complication of retroperitoneal surgery, and…”
Get full text